CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1593049
Combination of platinum-based chemotherapy and bemarituzumab in a young adult patient with NBN-mutated, FGFR2b-positive, and microsatellite stable (MSS) unresectable advanced gastric cancer: a rare clinical case report and literature review
Provisionally accepted
- Lanzhou University Second Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Patients with advanced and developed gastric cancer (GC) are often accompanied by severe metastasis. Anticancer drug therapy regimen has become the standard treatment for metastatic GC, and platinum-based chemotherapy has maintained its preeminent position in the first-line treatment regimens. Combination therapy for advanced gastric cancer, such as the use of zolbetuximab targeting Claudin18.2 in conjunction with a chemotherapy regimen, has extended the median progression-free survival(PFS) from 8.67 months to 10.61 months. While this combination therapy demonstrates notable efficacy for patients with advanced gastric cancer, only a minority of patients experience significant benefits. Therefore, further exploration and identification of more effective targets and combination treatment strategies remain imperative. Contrarily, FGFR2 overexpression has been identified as a biomarker of poor prognosis in GC, which is significantly correlated with poor survival. Recent clinical trial studies have revealed that the combination of chemotherapy with bemarituzumab, a monoclonal antibody targeting FGFR2b, significantly improved PFS compared with mFOLFOX6 chemotherapy alone in patients with FGFR2b-positive advanced GC. In addition, tumors with NBN mutation presenting as homologous recombination deficiency have increased sensitivity to platinum drugs.Here, we report a young adult patient with NBN mutated, FGFR2b-positive, microsatellite stable (MSS) advanced unresectable GC with peritoneal metastasis.After treatment with bemarituzumab combined with platinum drugs, the primary gastric tumor completely disappeared, and the peritoneal metastatic nodules became smaller and dormant. Pathological examination confirmed no tumor residuals. The patient's PFS has now reached 17 months. This case demonstrates that the combination of bemarituzumab and a platinum-based agent is a potential new option for conversion therapy in the first-line treatment of patients with NBN-mutated, FGFR2b-positive, MSS advanced unresectable GC.
Keywords: gastric cancer, NbN, FGFR2b, Bemarituzumab, combination therapy
Received: 13 Mar 2025; Accepted: 23 Jun 2025.
Copyright: © 2025 Ma, Liu, Liao, Li, Ma, Qi, Maswikiti, Chen and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hao Chen, Lanzhou University Second Hospital, Lanzhou, China
Zhijian Han, Lanzhou University Second Hospital, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.